Guardant Health Inc
NASDAQ:GH
Intrinsic Value
Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. [ Read More ]
The intrinsic value of one GH stock under the Base Case scenario is 21.6 USD. Compared to the current market price of 17.35 USD, Guardant Health Inc is Undervalued by 20%.
Valuation Backtest
Guardant Health Inc
Run backtest to discover the historical profit from buying and selling GH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Guardant Health Inc
Current Assets | 1.3B |
Cash & Short-Term Investments | 1.2B |
Receivables | 88.8m |
Other Current Assets | 89.7m |
Non-Current Assets | 439.3m |
PP&E | 302.7m |
Intangibles | 12.3m |
Other Non-Current Assets | 124.3m |
Current Liabilities | 205.9m |
Accounts Payable | 51.7m |
Accrued Liabilities | 136.2m |
Other Current Liabilities | 18m |
Non-Current Liabilities | 1.4B |
Long-Term Debt | 1.1B |
Other Non-Current Liabilities | 281.9m |
Earnings Waterfall
Guardant Health Inc
Revenue
|
563.9m
USD
|
Cost of Revenue
|
-227.1m
USD
|
Gross Profit
|
336.9m
USD
|
Operating Expenses
|
-901.6m
USD
|
Operating Income
|
-564.7m
USD
|
Other Expenses
|
85.3m
USD
|
Net Income
|
-479.4m
USD
|
Free Cash Flow Analysis
Guardant Health Inc
GH Profitability Score
Profitability Due Diligence
Guardant Health Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Guardant Health Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
GH Solvency Score
Solvency Due Diligence
Guardant Health Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Guardant Health Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GH Price Targets Summary
Guardant Health Inc
According to Wall Street analysts, the average 1-year price target for GH is 39.84 USD with a low forecast of 27.27 USD and a high forecast of 56.7 USD.
Ownership
GH Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
GH Price
Guardant Health Inc
Average Annual Return | -3.49% |
Standard Deviation of Annual Returns | 56.97% |
Max Drawdown | -91% |
Market Capitalization | 2.1B USD |
Shares Outstanding | 121 713 000 |
Percentage of Shares Shorted | 6.54% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.
Contact
IPO
Employees
Officers
The intrinsic value of one GH stock under the Base Case scenario is 21.6 USD.
Compared to the current market price of 17.35 USD, Guardant Health Inc is Undervalued by 20%.